These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

578 related items for PubMed ID: 17496166

  • 61. The selective CXCR2 antagonist SB272844 blocks interleukin-8 and growth-related oncogene-alpha-mediated inhibition of spontaneous neutrophil apoptosis.
    Glynn PC, Henney E, Hall IP.
    Pulm Pharmacol Ther; 2002; 15(2):103-10. PubMed ID: 12090783
    [Abstract] [Full Text] [Related]

  • 62. Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer.
    Nasser MW, Raghuwanshi SK, Grant DJ, Jala VR, Rajarathnam K, Richardson RM.
    J Immunol; 2009 Sep 01; 183(5):3425-32. PubMed ID: 19667085
    [Abstract] [Full Text] [Related]

  • 63. A small-molecule antagonist of CXCR1 and CXCR2 inhibits cell proliferation, migration and invasion in melanoma via PI3K/AKT pathway.
    Shang FM, Li J.
    Med Clin (Barc); 2019 Jun 07; 152(11):425-430. PubMed ID: 30340844
    [Abstract] [Full Text] [Related]

  • 64. Dynamic regulation of CXCR1 and CXCR2 homo- and heterodimers.
    Martínez Muñoz L, Lucas P, Navarro G, Checa AI, Franco R, Martínez-A C, Rodríguez-Frade JM, Mellado M.
    J Immunol; 2009 Dec 01; 183(11):7337-46. PubMed ID: 19890050
    [Abstract] [Full Text] [Related]

  • 65. Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region.
    Aki C, Chao J, Ferreira JA, Dwyer MP, Yu Y, Chao J, Merritt RJ, Lai G, Wu M, Hipkin RW, Fan X, Gonsiorek W, Fosseta J, Rindgen D, Fine J, Lundell D, Taveras AG, Biju P.
    Bioorg Med Chem Lett; 2009 Aug 01; 19(15):4446-9. PubMed ID: 19525110
    [Abstract] [Full Text] [Related]

  • 66. Pharmacological targeting reveals distinct roles for CXCR2/CXCR1 and CCR2 in a mouse model of arthritis.
    Min SH, Wang Y, Gonsiorek W, Anilkumar G, Kozlowski J, Lundell D, Fine JS, Grant EP.
    Biochem Biophys Res Commun; 2010 Jan 01; 391(1):1080-6. PubMed ID: 20004647
    [Abstract] [Full Text] [Related]

  • 67.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 68. Probing the role of CXC motif in chemokine CXCL8 for high affinity binding and activation of CXCR1 and CXCR2 receptors.
    Joseph PR, Sarmiento JM, Mishra AK, Das ST, Garofalo RP, Navarro J, Rajarathnam K.
    J Biol Chem; 2010 Sep 17; 285(38):29262-9. PubMed ID: 20630874
    [Abstract] [Full Text] [Related]

  • 69.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 70. Distribution of the interleukin-8 receptors, CXCR1 and CXCR2, in inflamed gut tissue.
    Williams EJ, Haque S, Banks C, Johnson P, Sarsfield P, Sheron N.
    J Pathol; 2000 Dec 17; 192(4):533-9. PubMed ID: 11113872
    [Abstract] [Full Text] [Related]

  • 71. 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.
    Allegretti M, Bertini R, Cesta MC, Bizzarri C, Di Bitondo R, Di Cioccio V, Galliera E, Berdini V, Topai A, Zampella G, Russo V, Di Bello N, Nano G, Nicolini L, Locati M, Fantucci P, Florio S, Colotta F.
    J Med Chem; 2005 Jun 30; 48(13):4312-31. PubMed ID: 15974585
    [Abstract] [Full Text] [Related]

  • 72. hCXCR1 and hCXCR2 antagonists derived from combinatorial peptide libraries.
    Houimel M, Mazzucchelli L.
    Cytokine; 2012 Mar 30; 57(3):322-31. PubMed ID: 22189418
    [Abstract] [Full Text] [Related]

  • 73. Inhibition of interleukin 8/C‑X-C chemokine receptor 1,/2 signaling reduces malignant features in human pancreatic cancer cells.
    Fu S, Chen X, Lin HJ, Lin J.
    Int J Oncol; 2018 Jul 30; 53(1):349-357. PubMed ID: 29749433
    [Abstract] [Full Text] [Related]

  • 74. CXCR1/2 antagonism with CXCL8/Interleukin-8 analogue CXCL8(3-72)K11R/G31P restricts lung cancer growth by inhibiting tumor cell proliferation and suppressing angiogenesis.
    Khan MN, Wang B, Wei J, Zhang Y, Li Q, Luan X, Cheng JW, Gordon JR, Li F, Liu H.
    Oncotarget; 2015 Aug 28; 6(25):21315-27. PubMed ID: 26087179
    [Abstract] [Full Text] [Related]

  • 75. Antibodies against the N-terminus of IL-8 receptor A inhibit neutrophil chemotaxis.
    Quan JM, Martin TR, Rosenberg GB, Foster DC, Whitmore T, Goodman RB.
    Biochem Biophys Res Commun; 1996 Feb 15; 219(2):405-11. PubMed ID: 8605000
    [Abstract] [Full Text] [Related]

  • 76. Bradykinin increases the in vivo expression of the CXC chemokine receptors CXCR1 and CXCR2 in patients with allergic rhinitis.
    Eddleston J, Christiansen SC, Jenkins GR, Koziol JA, Zuraw BL.
    J Allergy Clin Immunol; 2003 Jan 15; 111(1):106-12. PubMed ID: 12532104
    [Abstract] [Full Text] [Related]

  • 77.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 78. On the mechanism and significance of ligand-induced internalization of human neutrophil chemokine receptors CXCR1 and CXCR2.
    Rose JJ, Foley JF, Murphy PM, Venkatesan S.
    J Biol Chem; 2004 Jun 04; 279(23):24372-86. PubMed ID: 15028716
    [Abstract] [Full Text] [Related]

  • 79. Humanized forms of the CXCR1/CXCR2 antagonist, bovine CXCL8((3-74))K11R/G31P, effectively block ELR-CXC chemokine activity and airway endotoxemia pathology.
    Zhao X, Li F, Town JR, Zhang X, Wang W, Gordon JR.
    Int Immunopharmacol; 2007 Dec 15; 7(13):1723-31. PubMed ID: 17996682
    [Abstract] [Full Text] [Related]

  • 80.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.